Cargando…

Long-term lutein administration attenuates retinal inflammation and functional deficits in early diabetic retinopathy using the Ins2(Akita/+) mice

INTRODUCTION: Lutein is a carotenoid whose protective effects in the retina have been reported in various studies. The effect of lutein has not been reported in the retina of the Ins2(Akita/+) mouse, a well-characterized genetic model for diabetic retinopathy (DR) in which the etiology of diabetes i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wei, Tam, Ka Cheung, Ng, Tsz Chung, Goit, Rajesh Kumar, Chan, Kate Lok San, Lo, Amy Cheuk Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365433/
https://www.ncbi.nlm.nih.gov/pubmed/32665315
http://dx.doi.org/10.1136/bmjdrc-2020-001519
_version_ 1783560033576943616
author Wang, Wei
Tam, Ka Cheung
Ng, Tsz Chung
Goit, Rajesh Kumar
Chan, Kate Lok San
Lo, Amy Cheuk Yin
author_facet Wang, Wei
Tam, Ka Cheung
Ng, Tsz Chung
Goit, Rajesh Kumar
Chan, Kate Lok San
Lo, Amy Cheuk Yin
author_sort Wang, Wei
collection PubMed
description INTRODUCTION: Lutein is a carotenoid whose protective effects in the retina have been reported in various studies. The effect of lutein has not been reported in the retina of the Ins2(Akita/+) mouse, a well-characterized genetic model for diabetic retinopathy (DR) in which the etiology of diabetes is better defined than the chemically induced diabetes. The objective of the present study is to investigate the effect of long-term administration of lutein in early stages of DR using the Ins2(Akita/+) mouse. RESEARCH DESIGN AND METHODS: Heterozygous male Ins2(Akita/+) and age-matched wild-type mice were used. Lutein was administered to the mice in drinking water starting 6 weeks old daily until analysis at 4.5, 6.5 or 9 months of age. Plain water served as non-treatment control. Microglia were immunostained with ionized calcium-binding adapter molecule 1 (Iba-1) and cluster of differentiation 68 (CD68) in retinal flat-mounts. Vascular endothelial growth factor (VEGF) level in the retina was assessed by enzyme-linked immunosorbent assay (ELISA). Vascular permeability was analyzed in retinal flat-mounts after fluorescein isothiocyanate (FITC)-dextran perfusion. Retinal occludin expression was assessed via Western blots. Retinal function was examined by electroretinography (ERG). RESULTS: Increased microglial reactivity was detected in the Ins2(Akita/+) mouse retina and was suppressed by lutein. Lutein administration also reduced the upregulation of VEGF in the Ins2(Akita/+) mouse retina. Increased vascular leakage and decreased occludin expression were observed in the Ins2(Akita/+) mouse retina, and these alterations were attenuated by lutein treatment. ERG recordings showed reduced a-wave and b-wave amplitudes in the Ins2(Akita/+) mice. With lutein treatment, the ERG deficits were significantly alleviated. CONCLUSIONS: We showed beneficial effects of long-term lutein administration in the Ins2(Akita/+) mouse retina, including suppression of retinal inflammation, protection of retinal vasculature and preservation of retinal function. These results point to lutein’s potential as a long-term therapeutic intervention for prevention of inflammation and retinal degeneration in patients with early DR.
format Online
Article
Text
id pubmed-7365433
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-73654332020-07-21 Long-term lutein administration attenuates retinal inflammation and functional deficits in early diabetic retinopathy using the Ins2(Akita/+) mice Wang, Wei Tam, Ka Cheung Ng, Tsz Chung Goit, Rajesh Kumar Chan, Kate Lok San Lo, Amy Cheuk Yin BMJ Open Diabetes Res Care Emerging Technologies, Pharmacology and Therapeutics INTRODUCTION: Lutein is a carotenoid whose protective effects in the retina have been reported in various studies. The effect of lutein has not been reported in the retina of the Ins2(Akita/+) mouse, a well-characterized genetic model for diabetic retinopathy (DR) in which the etiology of diabetes is better defined than the chemically induced diabetes. The objective of the present study is to investigate the effect of long-term administration of lutein in early stages of DR using the Ins2(Akita/+) mouse. RESEARCH DESIGN AND METHODS: Heterozygous male Ins2(Akita/+) and age-matched wild-type mice were used. Lutein was administered to the mice in drinking water starting 6 weeks old daily until analysis at 4.5, 6.5 or 9 months of age. Plain water served as non-treatment control. Microglia were immunostained with ionized calcium-binding adapter molecule 1 (Iba-1) and cluster of differentiation 68 (CD68) in retinal flat-mounts. Vascular endothelial growth factor (VEGF) level in the retina was assessed by enzyme-linked immunosorbent assay (ELISA). Vascular permeability was analyzed in retinal flat-mounts after fluorescein isothiocyanate (FITC)-dextran perfusion. Retinal occludin expression was assessed via Western blots. Retinal function was examined by electroretinography (ERG). RESULTS: Increased microglial reactivity was detected in the Ins2(Akita/+) mouse retina and was suppressed by lutein. Lutein administration also reduced the upregulation of VEGF in the Ins2(Akita/+) mouse retina. Increased vascular leakage and decreased occludin expression were observed in the Ins2(Akita/+) mouse retina, and these alterations were attenuated by lutein treatment. ERG recordings showed reduced a-wave and b-wave amplitudes in the Ins2(Akita/+) mice. With lutein treatment, the ERG deficits were significantly alleviated. CONCLUSIONS: We showed beneficial effects of long-term lutein administration in the Ins2(Akita/+) mouse retina, including suppression of retinal inflammation, protection of retinal vasculature and preservation of retinal function. These results point to lutein’s potential as a long-term therapeutic intervention for prevention of inflammation and retinal degeneration in patients with early DR. BMJ Publishing Group 2020-07-14 /pmc/articles/PMC7365433/ /pubmed/32665315 http://dx.doi.org/10.1136/bmjdrc-2020-001519 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Emerging Technologies, Pharmacology and Therapeutics
Wang, Wei
Tam, Ka Cheung
Ng, Tsz Chung
Goit, Rajesh Kumar
Chan, Kate Lok San
Lo, Amy Cheuk Yin
Long-term lutein administration attenuates retinal inflammation and functional deficits in early diabetic retinopathy using the Ins2(Akita/+) mice
title Long-term lutein administration attenuates retinal inflammation and functional deficits in early diabetic retinopathy using the Ins2(Akita/+) mice
title_full Long-term lutein administration attenuates retinal inflammation and functional deficits in early diabetic retinopathy using the Ins2(Akita/+) mice
title_fullStr Long-term lutein administration attenuates retinal inflammation and functional deficits in early diabetic retinopathy using the Ins2(Akita/+) mice
title_full_unstemmed Long-term lutein administration attenuates retinal inflammation and functional deficits in early diabetic retinopathy using the Ins2(Akita/+) mice
title_short Long-term lutein administration attenuates retinal inflammation and functional deficits in early diabetic retinopathy using the Ins2(Akita/+) mice
title_sort long-term lutein administration attenuates retinal inflammation and functional deficits in early diabetic retinopathy using the ins2(akita/+) mice
topic Emerging Technologies, Pharmacology and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365433/
https://www.ncbi.nlm.nih.gov/pubmed/32665315
http://dx.doi.org/10.1136/bmjdrc-2020-001519
work_keys_str_mv AT wangwei longtermluteinadministrationattenuatesretinalinflammationandfunctionaldeficitsinearlydiabeticretinopathyusingtheins2akitamice
AT tamkacheung longtermluteinadministrationattenuatesretinalinflammationandfunctionaldeficitsinearlydiabeticretinopathyusingtheins2akitamice
AT ngtszchung longtermluteinadministrationattenuatesretinalinflammationandfunctionaldeficitsinearlydiabeticretinopathyusingtheins2akitamice
AT goitrajeshkumar longtermluteinadministrationattenuatesretinalinflammationandfunctionaldeficitsinearlydiabeticretinopathyusingtheins2akitamice
AT chankateloksan longtermluteinadministrationattenuatesretinalinflammationandfunctionaldeficitsinearlydiabeticretinopathyusingtheins2akitamice
AT loamycheukyin longtermluteinadministrationattenuatesretinalinflammationandfunctionaldeficitsinearlydiabeticretinopathyusingtheins2akitamice